Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference. I would like now to turn the conference over to George Grofik, Senior Vice President and Head of Investor Relations and Communication. Please go ahead, sir.

Good morning, and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's Fourth Quarter and Full Year 2024 results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com. Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer you to our most recent 10-Q on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial results. The reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Marshall Urist, EVP, Head of Research and Investments; Chris Hite, EVP, Vice Chairman; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss key highlights, after which Marshall will provide updates on our transaction pipeline and portfolio. Terry will then review the financials and following concluding remarks from Pablo, we will hold a Q&A session. And with that, I'd like to turn the call over to Pablo.

Thank you, George, and welcome to everyone on the call. It gives me great pleasure to report another successful year of execution against our strategy as the leading funder of innovation and life sciences. Moving to Slide 6. We're very proud of our achievements in 2024. We again delivered excellent financial performance and significantly enhanced our portfolio through strong capital deployment. We delivered Portfolio Receipts or top line of $2.8 billion for the year, which was at the high end of our guidance range. In underlying terms, this represents growth of 13% and Royalty Receipts and continues our track record of strong performance since our IPO. I should also point out that our 13% growth significantly exceeded our initial guidance of 5% to 9%. When we look to 2025 we’re expecting Portfolio Receipts of $2.9 billion to $3.05 billion. In terms of our portfolio, we added royalties on AD therapy, including four development stage therapies. We saw positive news across our portfolio including FDA approval of Voranigo for brain cancer, Cobenfy for schizophrenia and Tremfya for ulcerative colitis. And FDA acceptance of the NDA for Cytokinetics, aficamten, for obstructive hypertrophic cardiomyopathy. In terms of capital allocation, we had a very attractive year for royalty transactions, and we deployed capital of $2.8 billion to further broaden our portfolio as well as $230 million on share repurchases. Last month, we announced an evolution in our capital allocation framework in which we will scale our buybacks depending on the discount of our share price to intrinsic value. As part of this, our Board authorized a new $3 billion share repurchase plan, and our intention is to repurchase $2 billion in 2025. In the past month, we also generated over $0.5 billion in cash by monetizing the MorphoSys development funding bonds, which we will redeploy. Lastly, at the start of 2025, we announced a truly transformative step in the evolution of Royalty Pharma with a planned acquisition of our external manager to become an integrated company. We expect multiple strategic and financial benefits from this highly compelling internalization transaction, which we anticipate will close in the second quarter of this year. Moving to Slide 7, this highlights the journey we have been on since I started the business in 1996 from a closed and serial fund to an ongoing business with an investment life then moving through an expansion of our investment scope to our IPO in June of 2020. Last month's announcement of the internalization of the manager is the logical next step in our evolution and best position Royalty Pharma for future growth and shareholder value creation. Slide 8 gives more background on Royalty Pharma's current structure. The company has been externally managed since its creation in 1996. Under this structure, which is common among alternative asset managers, Royalty Pharma owns its unique industry-leading loyalty portfolio of more than 35 approved products and 14 development stage therapies, which includes 15 blockbuster therapies, but it has no employees. Instead, it pays a management fee of 6.5% of portfolio receipts at top line to the manager, which in turn provides the platform. Following the internalization, the intellectual capital will transfer entirely to Royalty Pharma and the company will integrate the employees and scale the investment platform into one entity. Importantly, now that Royalty Pharma will own the unique engine of future investment, we believe that Royalty Pharma shares will reflect the value of the world-class investment platform on top of the value of our kind portfolio volume on leading biopharmaceutical products. Slide 9 provides more detail on the multiple benefits for shareholders from the internalization. Financially, we expect cash savings from extinguishing the management fee will accumulate over time. In 2026, we expect savings of over $100 million, and over the next 10 years, cumulative savings are expected to be greater than $1.6 billion. This compares to the total consideration of $1.1 billion. In addition, by ending the management fee, the net returns on royalty investments will increase for shareholders. There are many important benefits. First, management and shareholders' alignment will be substantially strengthened given the majority of the consideration will be paid in stock investing for 5 years to 9 years. Second, with all employees transferring to Royalty Pharma, this ensures continuity of personnel and operations with long-term equity vesting to maximize retention. Third, it enhances our commitment to robust governance practices. Lastly, simplification will increase comparability of Royalty Pharma to other companies and enhance transparency. We think this transaction is highly compelling for shareholders and further strengthens our prospects for long-term value creation and success. With that, I will hand it over to Chris.

Thanks, Pablo. I want to give a brief update on our transaction pipeline and the tremendous opportunity set ahead of us. Slide 11 shows our transaction funnel. We're busy in 2024 reviewing more than 440 potential royalty transactions. This was a record for us and an increase of around 10% versus the prior year. This speaks to the strong secular tailwinds driving the demand for royalty financing as well as our competitive moats as the clear market leader. While we then move down the funnel, these initial reviews resulted in 153 confidentiality agreements signed, 99 in-depth reviews and 42 proposals submitted. We continue to be disciplined and highly selective on our approach as we executed only 8 transactions or just 2% of our initial reviews for a total transaction value of $2.8 billion. You can see on this slide the 8 potential new therapies on which we will receive royalties, which are nicely balanced between approved and development stage therapies. The therapies have blockbuster or even multi-blockbuster potential. Slide 12 provides an update on one of the fastest-growing parts of our opportunity set, namely synthetic royalties. This innovative solution involves creating new royalties as a non-dilutive funding solution for our partners. There are many reasons why this represents a true win-win approach for our partners. It allows us to tailor a solution to meet their needs, provides independent validation of the asset, and allows the partner to retain operational control. It aligns our long-term interest. And lastly, we can add value through our proprietary analytics. Biopharma funding has historically been dominated by equity licensing deals and debt. Synthetic royalties have represented less than 5% of overall funding. We are confident this proportion will increase based on our ongoing partnership discussions, which feel that synthetic royalties are being routinely discussed at the board level and C-suite as an important funding modality. Consistent with this growing opportunity, we achieved a record year for synthetic royalty transactions of $925 million in 2024. This figure has more than doubled since 2020. With the advantages I described and the huge funding requirements for life sciences innovation, we see tremendous scope for further growth in synthetic royalty funding. With that, I'll hand it over to Marshall.

Thanks, Chris. I want to focus today on an exciting group of five products from recent royalty transactions that are launching this year and will contribute to Royalty Pharma's growth in 2025 and beyond. Slide 14 summarizes these five launching therapies. What stands out as their novelty being either first or best-in-class in covering a diversity of diseases and technologies. This underscores our well-honed therapeutic area agnostic approach that focuses on transformational science and patient need. Touching on each of these. We see a large and underappreciated royalty opportunity from Voranigo in brain cancer based on our double-digit royalty potentially exceeding $150 million in annual Royalty Receipts. The Voranigo launch is tracking well, and we are excited to see additional progress in 2025. You are probably well aware of Cobenfy, Bristol's new treatment for schizophrenia. Consensus estimates point to significant sales potential, which we generate as much as $100 million in peak royalties. Geron's Rytelo and Ascendis' Yorvipath are off to a good start and Niktimvo both launches are now underway. Putting all of this together, total consensus peak sales forecast for these five therapies amount to over $10 billion, which would add over $430 million to annual portfolio receipts after applying their respective royalty rates. This scale of revenue contribution from just one year of new investment activity is clearly very meaningful in the context of our 2024 portfolio receipts of $2.8 billion. Furthermore, when you layer these launches on top of our development stage pipeline of 14 therapies, our diversified base of portfolio receipts and the market opportunity that Chris highlighted, you can see why we feel confident that we will continue to generate strong returns and growth. And with that, I'll hand it over to Terry.

Thanks, Marshall. Let's move to Slide 16. This slide shows how our efficient business model generates substantial cash flow to be reinvested. Royalty Receipts grew by 12% in the fourth quarter and 13% for the year, reflecting the strength of our diversified portfolio. Key drivers were the strong performance in the cystic fibrosis franchise, Trelegy, and others. The decrease for the year in portfolio receipts was primarily reflected in one-time Biohaven-related milestone payments received in 2023. As we move down the column, operating and professional costs equated to 9.8% of portfolio received in the fourth quarter and 8.4% for the year, consistent with our guidance. Net interest in the fourth quarter was de minimis, reflecting the timing of our interest payments in the first and third quarters. Full year net interest paid was $113 million. You should note that this did not reflect interest on the $1.5 billion of incremental debt that we raised this past summer, with the first interest payments from those new tranches expected in the first quarter of 2025. Moving further down the column, we've consistently stated that when we think of the cash generated by the business to then be redeployed into value-enhancing royalties, we look to portfolio cash flow which is adjusted EBITDA less net interest paid. This amounted to $678 million in the quarter, equivalent to a margin of 91%. On a full-year basis, portfolio cash flow was $2.45 billion, a margin of just under 88%. This high level of cash conversion once again underscores the efficiency of our business model. Capital deployment in the third quarter was $552 million, taking our total through the year to approximately $2.8 billion. Slide 17 shows that our unique business model has powered strong royalty receipts growth since our IPO. We delivered double-digit growth in 3 of the 4 years since our IPO, with an average annual growth over the period of 12%. We are particularly proud of this track record of consistent strong growth. Slide 18 provides more detail on the evolution of our top line in 2024. As I highlighted earlier, significant Biohaven-related payments in 2023 impacted year-over-year comparisons for portfolio receipts. Royalty Receipts, which we consider our recurring cash inflows, grew by 13%, which was well ahead of our initial guidance of around 5% to 9%. Importantly, as you can see on this slide, strong base business performance was the primary driver of our royalty receipts performance in 2024. Slide 19 shows that we continue to maintain significant financial capacity to execute our strategy through a combination of cash on our balance sheet, cash our business generates and access to the debt markets. At the end of the year, we had cash and equivalents of $929 million. We also include the proceeds from the MorphoSys development funding bonds in January. Our cash and equivalents stood at just over $1.4 billion on a pro forma basis. On the MorphoSys development funding bonds, we received proceeds of $511 million on the sale, which results in an IRR on that investment of approximately 25%. In terms of our borrowing position, we have investment grade debt outstanding of $7.8 billion. Leverage now stands at around 3x total debt to EBITDA. We also have undrawn financial capacity from a $1.8 billion revolver. We continue to take note of the fundamental disconnect on our share price and repurchased $50 million of our shares in the fourth quarter, taking our total spend on buybacks to $230 million during 2024. As a reminder, we announced a $3 billion share repurchase authorization on January 10. We will provide an update on our progress on net new authorization on our first quarter earnings call. Slide 20 lays out our capital allocation framework. We have a dynamic framework, which balances our view of the share price valuation against the attractiveness of royalty deals. When our share price is trading at a discount to its intrinsic value, share buybacks will be an important part of our capital allocation. Conversely, when our shares approach a premium to intrinsic value we would plan to dial back our share repurchases and focus on higher returning royalty deals. In an environment where neither attractive royalty deals nor share repurchases are available, you have other options available for our cash, including growing cash to wait for the right deals, paying down debt or increasing dividend distributions. Ultimately, we are focused on driving shareholder value through allocating capital as efficiently and effectively as possible. Today, we believe we're operating in the upper left quadrant, where we see many attractive royalty opportunities and a discount to the intrinsic value of our stock. For this reason, we announced a new $3 billion share repurchase program last month with an intention to repurchase up to $2 billion of shares in 2025 depending on the level of discount to intrinsic value. Slide 21 provides more granular detail on the evolution of our balanced capital allocation framework to drive shareholder returns. We expect to maintain significant financial capacity to execute royalty deals in 2025, consistent with our guidance of between $2 billion and $2.5 billion of capital deployment per year on average. We are maintaining our investment target returns, but also note that IRRs have trended higher in recent years. We also maintain a strong commitment to an investment-grade credit rating. Lastly, there’s no change to our dividend policy, which is to grow by a mid-single-digit percentage annually. Slide 22 provides our full year 2025 financial guidance. We expect portfolio receipts to be in the range of $2.9 billion to $3.05 billion, which equates to growth of around 4% to 9%. This guidance reflects the momentum of our diversified portfolio. It also takes into account a range of scenarios for the launch of new therapies, as well as for generics, biosimilars and the impact of Medicare Part D redesign. Other contractual receipts are expected to increase from $31 million in 2024 to approximately $60 million in 2025. The $511 million upfront for monetization of the MorphoSys development funding bonds will not be recorded in portfolio receipts and will instead be treated as an asset sale. Importantly, consistent with our standard practice, this guidance is based on our portfolio as of today. It does not take into account the benefit of any future royalty acquisition. You would also note that our top line would have been approximately $150 million higher in 2025 if the long-term payments relating to Biohaven and MorphoSys had not been accelerated, which increased the IRRs on both of those investments. Turning to operating costs. Payments for operating and professional costs are expected to be approximately 10% of portfolio receipts in 2025, lending efficiency to our business model. This figure takes into account one-time expenses related to the MorphoSys development funding bond sale to increase operating and professional costs by around 1 percentage point. Furthermore, our guidance does not take into account the benefit of the internalization transaction. We will provide an update after it closes. Interest paid in 2025 is expected to be around $250 million with minimal amounts due in Q2 and Q4. The year-over-year increase reflects interest payments from the $1.5 billion of notes issued in June of 2024 for which the first payment is due in the first quarter. This guidance does not take into account interest received on our cash balance, which was $9 million in the fourth quarter of 2024 and $46 million in the full year. It also does not reflect the additional interest expense, which will follow the internalization transaction. As a final consideration, while share repurchases would clearly decrease our average share count in 2025, there will be a slight offset from the issuance of equity performance awards, which is our long-term incentive compensation program, which reflects the success of our investments in 2020 and 2021. We expect equity performance awards to be approximately $45 million in 2025. It’s approximately half of that value reflected in the share count over the course of the year. In closing, we expect to deliver another year of strong financial performance in 2025. We are excited by the opportunity to accelerate shareholder value through our new share repurchase program and the internalization transaction.

Thanks, Terry. Let's move to Slide 24 for a summary of the key messages you have heard today. First, we delivered solid performance with 3% growth in royalty receipts in 2024, during which we significantly exceeded our initial guidance. We also deployed substantial capital of $2.8 billion as we acquired 8 exciting new royalties, adding further diversification and long-term growth. Second, we continue to have a very attractive opportunity set we conducted initial reviews on over 440 potential royalty transactions, a new record for Royalty Pharma, which speaks both to the fast-growing demand for royalty funding and to our continued leadership position. We did so in a very disciplined manner. In order to drive strong returns, which have trended higher in recent years. Third, we have started 2025 with two important steps to further enhance shareholder value with our new $3 billion share repurchase program and our internalization transaction. Also considered I'm confident that Royalty Pharma is increasingly well positioned to deliver attractive compounding growth and to drive value for shareholders. With that, we will be happy to take your questions.

And the first question will come from Geff Meacham with Citi.

Thanks for the question. Just had a few. Terry, on the guidance, I know you don't want to provide a point estimate, but maybe if you give us any additional detail on the lift truck assumptions that you're making for the year. Same on the launch. And I know MorphoSys isn't included, but are there any milestones assumed in the portfolio received guidance? And the second question, more bigger picture for Pablo. I know we've seen a lot of new policies coming out of D.C. sort of fast and furious, what would you say are other risks to royalties from maybe a tax or IRI perspective? I wasn't sure if you guys had engagement with the new administration or taken more of a reactive stance?

Sure, Geff. So on the guidance, we haven't provided specific product-by-product guidance; that’s not our normal practice. I just for Alyftrek and the other launch, as you can imagine, you looked at a range of scenarios for both of those and continue to believe that they will be the CF franchise will continue to be a very important contributor for Royalty Pharma in 2025 and also over the long term. And also, we expect that Tysabri will continue to be a very important contributor for Royalty Pharma. But yes, as far as specifics, we haven't given anything but looked at a range of scenarios. In terms of milestones assumed in our 2025 guidance, we assumed $60 million or so of milestones. So not a particularly large component of the portfolio received guidance for this year.

And also excluding the MorphoSys.

We received a payment from the other launch in the first quarter, which is relatively small. However, the significant $511 million related to the sale of MorphoSys development funding bonds is not included in that guidance since it was classified as an asset sale, so it will not appear in our portfolio receipts.

So with respect to your bigger picture question of the new administration and the initiatives related to health care. It's early days, Geff. We're following very closely. In terms of your question regarding taxes, we don’t foresee any impact or any change in the taxation of our business. And the other thing I would say is that we're fortunate to have on our Board, a member who is the Chairman of Bio. So I've been in discussions with him just to get insight on what's going on and how the industry is reacting. And another thing that we plan to do is to get more involved through the industry associations with the administration.

And our next question comes from Chris Schott with JPMorgan.

I have two questions. First, could you discuss the returns on synthetic royalties compared to more traditional structures? I’m interested in whether the growth in this newer source of royalties is driven by expanding the market and asset options or if you expect higher returns as well. Second, regarding the Vertex royalty and the Alyftrek launch, could you clarify the timing of the arbitration process and when we might gain more visibility on the royalty situation?

Sure. Thanks for the question. So Chris, why don't you take the question on synthetic royalties, the scale of the opportunity and the returns. And then Terry can talk about Vertex and the timing we expect.

Thank you for the question, Chris. We had a record year last year in synthetic opportunities, and the trends are very positive. We've noticed a significant shift in the sector's mindset. Over the past five years, the sector has increasingly adopted alternative capital forms, particularly synthetic royalties, when raising funds for their businesses instead of partnering with pharmaceuticals or pursuing equity or debt. Partnering with pharma often means relinquishing some operational control, especially U.S. rights. Companies find our capital attractive since they maintain operational control and can continue marketing in the U.S. This creates mutually beneficial solutions for them, as evidenced by the numerous deals we finalized last year. Regarding returns, we are confident in the return profile we achieve from these transactions, as we would not engage in them if we weren’t satisfied with the returns. We emphasize the mutually advantageous nature of these agreements and all the benefits involved when discussing our return profile. We are excited about both the returns and the opportunities that lie ahead.

And then just on track timing of arbitration. So just to reiterate what we said previously, we continue to feel really strongly about this. The position is the same as before. And so we do feel very confident in that position. In terms of the timing of any potential arbitration, we don't have an update right now. But what we can say is that arbitration unlike a typical court process, arbitration is not a long drawn-out process, but we can't really provide any specifics right now around timing.

And our next question will come from Michael Nedelcovych with TD Cowen.

I have two. My first is on guidance again. Going back at least to 2022, I believe Royalty Pharma's year-end performance in each year ended up outperforming your initial guidance by a healthy margin. Is it fair then to assume that the top line guidance for 2025 may be somewhat conservative? And my second question is on your screening process. From 440 reviews to only 8 transactions is very impressive; what would you say are the most common reasons that you do not pursue a given transaction?

Sure, Terry, why don’t you take the question on guidance and then Marshall the one on the funnel and our selection process.

Yes. So you’re correct that historically we have tended to outperform. And I think that's just kind of the nature of the types of products that we invest in, in the portfolio. It's just early right now. We're just starting the year. And so our range is a little bit wider, as you can imagine. But we feel like there's a lot of great momentum in the portfolio. We're very confident about how things are going and hope that as the year evolves, we can be heading towards higher numbers, but it's just early days right now.

Great. Thanks for your question on the funnel. So it's a good question. And the discipline that the funnel entails is something that is absolutely core to our investment process. We never feel compelled to do anything; it’s really focusing on the quality of the product, its importance to patients, the strength of our partners, the clinical data, the clinical profile, and the commercial potential of the intellectual property. So I think if you looked at the top of the funnel and what skinnies down all the opportunities that we look at. I do think it's probably spread pretty broadly across all of those things that I just mentioned. I think stage of development is an important one. IP can be another important factor. And then I think the product profile either in terms of if it's a development stage or a commercial stage plan. So it really is across the board. But I think that discipline and that focus on only adding really high-quality important products to the portfolio is sort of our North Star and what will continue to guide our process this year and beyond.

If I could briefly share a couple of additional insights on our investment approach and the pipeline, I want to emphasize that at Royalty Pharma, we have a long-standing practice of thoroughly exploring all available opportunities. We invest time engaging with management teams to understand their products, technology, and the underlying science. This approach provides us with valuable insight into how the ecosystem is evolving and what may become highly successful in the next 5 to 10 years. While we evaluate many early-stage projects, taking the time to listen to management allows us to gain a perspective on their plans. In some cases, we might suggest revisiting in a year or two, but having the chance to hear their story early on enables us to assess whether management has successfully executed their strategy. Thus, it is a dynamic process, and maintaining a broad scope is equally important.

And our next question comes from Chris Shibutani with Goldman Sachs.

Great. I always appreciate this quarter with the funnel. And if I go back to every slide every year over the past since the IPO, there's been a subsequent slide that talks about the growth in your capacity through each of those stages. And starting last year and also in this year, the highlight of strong growth in initial reviews was removed. Numerically, it has increased from mid-200s to 300, 350, 400; should we expect that pace of initial reviews to continue at this numeric level, though it is decelerating? And what are the constraints potentially to that? And with regard to constraints, the second question would be, can you talk to us about what your scope of access and exposure is globally? Industry certainly has been doing a lot more of searching and partnering of assets in particular late from China. Do you have a footprint there? Any thoughts? And should we look for you to perhaps become active? Or is that not an ecosystem that necessarily is embracing the royalty-based approach?

Marshall should address the question regarding the funnel and initial reviews. Our business operates on a global scale, and we have successfully made global investments for many years. Even without a physical presence in Europe, we managed to make significant investments in the past, such as in HUMIRA, where we acquired rights from various companies and technologies. Although we now have a presence in Europe, we are still actively exploring opportunities in China. We have made efforts to travel and engage with companies there and have also met them when they visit the U.S., which is quite common. If you examine the leading Chinese biotech firms that are developing impressive technologies and licensing them to Western companies, we have known them for 10 to 15 years and maintained ongoing conversations. We plan to enhance our engagement in China and intend to visit again this year. Marshall?

Yes. Chris, thanks for your question. I think what you point out is exactly right. I think our track record since the IPO and the growth in the number of opportunities I think, hopefully, has convinced everyone about what we saw when we went public, which is that we thought the opportunity for royalty-based funding or alternative forms of capital in biopharma was a big opportunity and something that we were excited about capturing. And I think that how the number of things that we have looked at, how the size of our market has scaled over the last 5 years since we went public has really proven that out. So I think that's the message from here. I think we will continue to have a very, very broad scope of opportunities to look at. But the important thing is that are we finding really impactful, important products to add to the portfolio. And I think when you look at what we did last year, that's a great example of exactly the kind of thing that we want to do every year adding really attractive launching products as well as adding to our pipeline of development-stage products as well. So I think that is how we see the world, and I think we're really excited about the opportunity in front of us. And as Pablo mentioned, I think what we've seen in terms of the licensing from Chinese products is a great example of how the ecosystem continues to expand. As there are royalties being created in licensing deals from China to multinational pharma companies that just adds another source of royalties for us and further expands the market opportunity. So we are really excited about the opportunity in front of us.

Chris, I want to emphasize that our business operates on a global scale. To capitalize on the substantial opportunities available, such as the over 400 prospects we reviewed last year, the size and scale of our investment team are critical. Royalty Pharma boasts one of the largest investment teams dedicated to life sciences, with a specific focus on our unique investment approach. Unlike many, we do not invest in equities, and there are countless public biotech companies that require different expertise. Our investment strategy is distinct, and our team is extensive with a global reach. This is another important point to highlight.

And our next question will come from Jason Gerberry with Bank of America Securities.

This is Dina on for Jason. Two from us. One, on the impact of the IRA Part D redesign, do you view the redesign as material? And are there any products you believe are mismodeled by the Street? How do you redesign elements impacting products with high Part D exposure such as olanzapine LAI? And then just a quick follow-up on the Vertex matter. Are you able to provide any color on your expectations that there will definitely be an official arbitration process versus the probability that there could be a more amicable resolution?

Sure. So Marshall, do you want to take the question on the impact of IRA? And maybe, George, you take the question on Vertex, or Terry actually.

Great. So just quickly on IRA, and Terry can add anything in terms of how we thought about it for guidance for 2025. So in a portfolio as broad as ours with some multi-blockbusters and important products we have in the portfolio, it is something we are watching. I think one of the important things we've highlighted overall is that when you take a step back and look at the portfolio, the IRA exposure, the initial Part D exposure is actually pretty modest. We've highlighted 3 products there, Imbruvica, which was, of course, on the list last year for price negotiation and then for this year, Xtandi and Trelegy. So completely as expected for us. And then I think beyond that in the portfolio, we will continue to watch how this evolves and some of the positives in terms of the lower out-of-pocket exposure as well and how that's balanced against the more negative aspects from a revenue perspective, but something we're definitely continuing to watch.

Regarding the Vertex matter, we are unable to provide any specific details about the arbitration at this time. Should we have any updates, we will certainly inform our investors then.

And our next question will come from Ash Verma with UBS.

Congrats on all the progress. So I have two questions. One is just on the guide for operating and professional costs at 10% of the portfolio receipts. I wanted to make sure this does not reflect the internalization yet? And then the $100 million savings that you had mentioned previously is that versus the 10% level or the prior 8% to 8.5% rate that you were at before? And then Alyftrek, to the extent that you can comment, I mean, would this have to be resolved before the first royalty received becomes due in Q1? Or can it go beyond that?

Sure. So the 10% operating professional cost guidance does not reflect the internalization. As we mentioned on our call on the internalization, we think that number following internalization would be around 4% to 5%. We continue to believe that would be the case. So that's probably what to think about for 2026 as an example, which would be the first full year post internalization. This year, it's just a little tough because it's going to be a split year of pre- and post-internalization. And the savings, the $100 million savings is reflected in that 4% to 5% of number that I gave. In terms of the Alyftrek, again, recognize that investors are here to learn more about timing. We just can't provide any specifics at this time and we would update investors at the appropriate time if there is an update.

I show no further questions in the queue at this time. I would like to turn the call back over to Pablo for closing remarks.

Thank you, operator, and thank you to everyone on the call for your continued interest in Royalty Pharma. I want to conclude by expressing our excitement about the closing of the internalization transaction in the coming months. We anticipate an exciting year ahead as we begin to realize the benefits of the internalization, our share repurchase program, and the ongoing deployment of our capital into promising products. If you have any follow-up questions, please feel free to reach out to George. Thank you.

This concludes today's conference call. Thank you for participating. You may now disconnect.